Highlights•Evaluating drug efficacy, specificity and toxicity may help to develop an optimal
treatment regime for in vivo studies.•Measuring time to resolve viremia in vivo may help to …

Hepatitis C virus (HCV) is an important human pathogen with a high chronicity rate. An
estimated 71 million people worldwide are living with chronic hepatitis C (CHC) infection …

Background & Aims Eight-week glecaprevir/pibrentasvir leads to high rates of sustained
virological response at post-treatment week 12 (SVR12) across HCV genotypes (GT) 1–6 in …

Recent global outbreak of the pandemic caused by coronavirus (COVID-19) emphasizes the
urgent need for novel antiviral therapeutics. It can be supplemented by utilization of efficient …

Abstract On June 8, 2018, an NS3/4A protease inhibitor called danoprevir was approved in
China to treat the infections of HCV genotype (GT) 1b–the most common HCV genotype …

Owing to the rapid development and wide clinical application of direct acting antiviral (DAA)
drugs in the treatment of hepatitis C virus (HCV) infection, the era of interferon-based …

Background and aim: undiagnosed hepatitis C virus (HCV) infection and/or inadequate
access to care are barriers to the elimination of HCV. Reflex testing has proven to facilitate …

Effectiveness of direct-acting antivirals for hepatitis C vi... : Medicine Effectiveness of direct-acting
antivirals for hepatitis C virus infection in hepatitis C/HIV coinfected individuals: A multicenter …

Protein kinases (PKs) are enzymes that catalyze the transfer of the terminal phosphate
group from ATP to a protein acceptor, mainly to serine, threonine, and tyrosine residues. PK …

Background The scale of HCV problem in Egypt prioritized the development of a national
control strategy that employs the use of locally manufactured generic direct-acting antivirals …